High-dose bevacizumab therapy may lead to less need for retreatment for ROP

• Posted on: Jun 1 2023
• By: Saratoga Opthalmology
• Leave a response

For retinopathy of prematurity (ROP), treating with high-dose bevacizumab vs low-dose bevacizumab or any dose of ranibizumab may mean a lower rate of retreatment.
Source: AAO

Posted in: Uncategorized